keyword
MENU ▼
Read by QxMD icon Read
search

HIV treatment failure

keyword
https://www.readbyqxmd.com/read/28424561/response-by-gender-of-hiv-1-infected-subjects-treated-with-abacavir-lamivudine-plus-atazanavir-with-or-without-ritonavir-for-144-weeks
#1
Kathleen E Squires, Benjamin Young, Lizette Santiago, Robin H Dretler, Sharon L Walmsley, Henry H Zhao, Gary E Pakes, Lisa L Ross, Mark S Shaefer
PURPOSE: The 144-week results of the open-label, multicenter Atazanavir/Ritonavir Induction with Epzicom Study (ARIES) were stratified by gender to compare treatment responses. METHODS: A total of 369 HIV-infected, antiretroviral-naïve subjects receiving once-daily abacavir/lamivudine + atazanavir/ritonavir (ATV/r) whose HIV-1 RNA was <50 copies/mL by week 30 were randomized 1:1 at week 36 to maintain or discontinue ritonavir for 108 subsequent weeks. Between- and within-treatment gender-related efficacy and safety differences were analyzed...
2017: HIV/AIDS: Research and Palliative Care
https://www.readbyqxmd.com/read/28419149/mobile-health-treatment-support-intervention-for-hiv-and-tuberculosis-in-mozambique-perspectives-of-patients-and-healthcare-workers
#2
José António Nhavoto, Åke Grönlund, Gunnar O Klein
BACKGROUND: Studies have been conducted in developing countries using SMS to communicate with patients to reduce the number of missed appointments and improve retention in treatment, however; very few have been scaled up. One possible reason for this could be that patients or staff are dissatisfied with the method in some way. This paper reports a study of patients' and healthcare workers' (HCW) views on an mHealth intervention aiming to support retention in antiretroviral therapy (ART) and tuberculosis (TB) treatment in Mozambique...
2017: PloS One
https://www.readbyqxmd.com/read/28418988/hiv-specific-cd8-t-cells-producing-ccl-4-are-associated-with-worse-immune-reconstitution-during-chronic-infection
#3
Rita Casetti, Carmela Pinnetti, Alessandra Sacchi, Gabriele De Simone, Veronica Bordoni, Eleonora Cimini, Nicola Tumino, Francesca Besi, Domenico Viola, Federica Turchi, Valentina Mazzotta, Andrea Antinori, Federico Martini, Adriana Ammassari, Chiara Agrati
BACKGROUND: Immunological non response represents the Achilles heel in the combination antiretroviral treatment (cART) effectiveness, and increases risk of clinical events and death. CD8 T cells play a crucial role in controlling HIV replication and polyfunctional HIV-specific CD8 T cells have been associated with non-progressive HIV infection. However, the possible role of polyfunctional CD8 T cells in predicting post-treatment immune reconstitution has not yet been explored. The aim of this study was to identify functional markers predictive of immunological response to cART in chronic HIV-infected patients...
April 7, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28416195/pitavastatin-versus-pravastatin-in-adults-with-hiv-1-infection-and-dyslipidaemia-intrepid-12-week-and-52-week-results-of-a-phase-4-multicentre-randomised-double-blind-superiority-trial
#4
Judith A Aberg, Craig A Sponseller, Douglas J Ward, Vladimir A Kryzhanovski, Stuart E Campbell, Melanie A Thompson
BACKGROUND: People living with HIV-1 infection are at greater risk for cardiovascular disease than seronegative adults. Treatment of dyslipidaemia with statins has been challenging in people with HIV because of an increased potential for drug interactions due to competing cytochrome P450 metabolism between statins and commonly used antiretroviral agents. Neither pitavastatin nor pravastatin depend on cytochrome P450 for primary metabolism. We aimed to assess the safety and efficacy of pitavastatin versus pravastatin in adults with HIV and dyslipidaemia...
April 13, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28404502/modelling-adverse-treatment-outcomes-of-hiv-infected-adolescents-attending-public-sector-hiv-clinics-in-lusaka
#5
I Fwemba, P Musonda
BACKGROUND: In resource-limited setting, there is scarce evidence comparing antiretroviral therapy (ART) outcomes among HIV-infected adolescents to that of other age groups. METHODS AND STUDY DESIGN: We analysed data from 25 ART facilities in Lusaka District, comparing treatment-naïve ART-eligible young adolescents (10-14 years), older adolescents (15-19) and young adults (20-24 years) initiating first-line ART to those aged 24 years or older. The adjusted relative risk (RR) of failure to achieve an adequate CD4 response (defined as failure to increase CD4 count by ≥ 50 cells/mm(3) at 6 months or by ≥ 100 cells/mm(3)) at 6 or 12 months after ART initiation was modelled using log-binomial regression...
March 6, 2017: Public Health
https://www.readbyqxmd.com/read/28399819/comparison-of-atazanavir-ritonavir-and-darunavir-ritonavir-based-antiretroviral-therapy-for-antiretroviral-na%C3%A3-ve-patients
#6
Tony Antoniou, Leah Szadkowski, Sharon Walmsley, Curtis Cooper, Ann N Burchell, Ahmed M Bayoumi, Julio S G Montaner, Mona Loutfy, Marina B Klein, Nima Machouf, Christos Tsoukas, Alexander Wong, Robert S Hogg, Janet Raboud
BACKGROUND: Atazanavir/ritonavir and darunavir/ritonavir are common protease inhibitor-based regimens for treating patients with HIV. Studies comparing these drugs in clinical practice are lacking. METHODS: We conducted a retrospective cohort study of antiretroviral naïve participants in the Canadian Observational Cohort (CANOC) collaboration initiating atazanavir/ritonavir- or darunavir/ritonavir-based treatment. We used separate Fine and Gray competing risk regression models to compare times to regimen failure (composite of virologic failure or discontinuation for any reason)...
April 11, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28398993/prevention-of-hiv-in-adolescent-girls-and-young-women-key-to-an-aids-free-generation
#7
Quarraisha Abdool Karim, Cheryl Baxter, Deborah Birx
The Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive (Global Plan) has ensured that more infants in high-HIV burden countries survive childhood HIV-free. Although equal numbers of boy and girl children have survived to age 10, a gender divergence starts to emerge as they enter adolescence. Up to 3 times as many young women aged 15-24 years in eastern and southern Africa are living with HIV compared with their male peers. Further, more adolescent girls and young women are sick and/or dying from AIDS-related or HIV-related complications during pregnancy and in the postpartum period, underscoring the importance of strengthening HIV treatment and prevention services for this group...
May 1, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28390164/-efficacy-and-safety-of-nucleoside-sparing-regimen-based-on-raltegravir-and-ritonavir-boosted-darunavir-in-hiv-1-infected-treatment-experienced-patients
#8
Elżbieta Jabłonowska, Piotr Pulik, Anna Kalinowska, Jacek Gąsiorowski, Miłosz Parczewski, Monika Bociąga-Jasik, Łukasz Pulik, Ewa Siwak, Kamila Wójcik
AIM: To assess the efficacy and tolerability of dual therapy containing raltegravir (RAL) and ritonavir boosted darunavir (DRV/r) in HIV-1-infected treatment-experienced patients.ethod. Retrospective analysis of 81 HIV-1-infected treatment-experienced patients (56 male and 25 female, 5 Polish centers) who switched to RAL/DRV/r. RESULTS: The main reasons for the introduction of dual therapy were renal dysfunction (16/81 patients - 19.8%) and virologic failure on previous regimens (15/81 patients - 18...
April 8, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/28387865/strengthening-hiv-therapy-and-care-in-rural-tanzania-affects-rates-of-viral-suppression
#9
Alex J Ntamatungiro, Lukas Muri, Tracy R Glass, Stefan Erb, Manuel Battegay, Hansjakob Furrer, Christoph Hatz, Marcel Tanner, Ingrid Felger, Thomas Klimkait, Emilio Letang
Objectives: To assess viral suppression rates, to assess prevalence of acquired HIV drug resistance and to characterize the spectrum of HIV-1 drug resistance mutations (HIV-DRM) in HIV-1-infected patients in a rural Tanzanian HIV cohort. Methods: This was a cross-sectional study nested within the Kilombero and Ulanga Antiretroviral Cohort. Virological failure was defined as HIV-1 RNA ≥50 copies/mL. Risk factors associated with virological failure and with the development of HIV-DRM were assessed using logistic regression...
April 6, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28387836/switching-to-second-line-art-in-relation-to-mortality-in-a-large-tanzanian-hiv-cohort
#10
Claudia Hawkins, Ellen Hertzmark, Donna Spiegelman, Aisa Muya, Nzovu Ulenga, Sehee Kim, Polyna Khudyakov, Beatrice Christian, David Sando, Eric Aris, Wafaie Fawzi
Objectives: In a large cohort of HIV-infected Tanzanians, we assessed: (i) rates of first-line treatment failure and switches to second-line ART; (ii) the effect of switching to second-line ART on death and loss to follow-up; and (iii) treatment outcomes on second-line ART by regimen. Methods: HIV-1-infected adults (≥15 years) initiated on first-line ART between November 2004 and September 2012, and who remained on initial therapy for at least 24 weeks before switching, were studied...
April 6, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28387447/withdrawn-interventions-for-fatigue-and-weight-loss-in-adults-with-advanced-progressive-illness
#11
REVIEW
Cathy Payne, Philip J Wiffen, Suzanne Martin
BACKGROUND: Fatigue and unintentional weight loss are two of the commonest symptoms experienced by people with advanced progressive illness. Appropriate interventions may bring considerable improvements in function and quality of life to seriously ill people and their families, reducing physical, psychological and spiritual distress. OBJECTIVES: To conduct an overview of the evidence available on the efficacy of interventions used in the management of fatigue and/or unintentional weight loss in adults with advanced progressive illness by reviewing the evidence contained within Cochrane reviews...
April 7, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28387147/tyrosine-kinase-inhibitors-potential-use-and-safety-considerations-in-hiv-1-infection
#12
Mayte Coiras, Juan Ambrosioni, Francisco Cervantes, José M Miró, José Alcamí
Infection caused by HIV-1 is nowadays a chronic disease due to a highly efficient antiretroviral treatment that is nevertheless, unable to eliminate the virus from the organism. New strategies are necessary in order to impede the formation of the viral reservoirs, responsible for the failure of the antiretroviral treatment to cure the infection. Areas covered: The purpose of this review is to discuss the possibility of using tyrosine kinase inhibitors (TKIs) for the treatment of HIV-1 infection. These inhibitors are successfully used in patients with distinct cancers such as chronic myeloid leukemia...
April 7, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28385131/virologic-outcomes-in-early-antiretroviral-treatment-hptn-052
#13
Susan H Eshleman, Ethan A Wilson, Xinyi C Zhang, San-San Ou, Estelle Piwowar-Manning, Joseph J Eron, Marybeth McCauley, Theresa Gamble, Joel E Gallant, Mina C Hosseinipour, Nagalingeswaran Kumarasamy, James G Hakim, Ben Kalonga, Jose H Pilotto, Beatriz Grinsztejn, Sheela V Godbole, Nuntisa Chotirosniramit, Breno Riegel Santos, Emily Shava, Lisa A Mills, Ravindre Panchia, Noluthando Mwelase, Kenneth H Mayer, Ying Q Chen, Myron S Cohen, Jessica M Fogel
INTRODUCTION: The HIV Prevention Trials Network (HPTN) 052 trial demonstrated that early antiretroviral therapy (ART) prevented 93% of HIV transmission events in serodiscordant couples. Some linked infections were observed shortly after ART initiation or after virologic failure. OBJECTIVE: To evaluate factors associated with time to viral suppression and virologic failure in participants who initiated ART in HPTN 052. METHODS: 1566 participants who had a viral load (VL) > 400 copies/mL at enrollment were included in the analyses...
April 7, 2017: HIV Clinical Trials
https://www.readbyqxmd.com/read/28384660/association-between-hiv-infection-and-the-risk-of-heart-failure-with-reduced-ejection-fraction-and-preserved-ejection-fraction-in-the-antiretroviral-therapy-era-results-from-the-veterans-aging-cohort-study
#14
Matthew S Freiberg, Chung-Chou H Chang, Melissa Skanderson, Olga V Patterson, Scott L DuVall, Cynthia A Brandt, Kaku A So-Armah, Ramachandran S Vasan, Kris Ann Oursler, John Gottdiener, Stephen Gottlieb, David Leaf, Maria Rodriguez-Barradas, Russell P Tracy, Cynthia L Gibert, David Rimland, Roger J Bedimo, Sheldon T Brown, Matthew Bidwell Goetz, Alberta Warner, Kristina Crothers, Hilary A Tindle, Charles Alcorn, Justin M Bachmann, Amy C Justice, Adeel A Butt
Importance: With improved survival, heart failure (HF) has become a major complication for individuals with human immunodeficiency virus (HIV) infection. It is unclear if this risk extends to different types of HF in the antiretroviral therapy (ART) era. Determining whether HIV infection is associated with HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), or both is critical because HF types differ with respect to underlying mechanism, treatment, and prognosis...
April 5, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/28382208/etravirine-combined-with-antiretrovirals-other-than-darunavir-ritonavir-for-hiv-1-infected-treatment-experienced-adults-week-48-results-of-a-phase-iv-trial
#15
Eduardo Arathoon, Asad Bhorat, Rodica Silaghi, Herta Crauwels, Ludo Lavreys, Lotke Tambuyzer, Ben Van Baelen, Simon Vanveggel, Magda Opsomer
OBJECTIVE: VIOLIN (TMC125IFD3002; NCT01422330) evaluated the safety, tolerability, and pharmacokinetics of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected patients. METHODS: In a 48-week, phase IV, single-arm, multicenter study, patients on prior antiretroviral therapy (⩾8 weeks) who needed to change regimen for virologic failure (viral load ⩾ 500 copies/mL) or simplification/adverse events (viral load < 50 copies/mL) received etravirine 200 mg bid with ⩾1 other active antiretroviral, excluding darunavir/ritonavir or only nucleoside/tide reverse transcriptase inhibitors...
2017: SAGE Open Medicine
https://www.readbyqxmd.com/read/28377526/the-r263k-dolutegravir-resistance-associated-substitution-progressively-decreases-hiv-1-integration
#16
Thibault Mesplède, Jing Leng, Hanh Thi Pham, Jiaming Liang, Yudong Quan, Yingshan Han, Mark A Wainberg
Human immunodeficiency virus (HIV) infection persists despite decades of active antiretroviral therapy (ART), effectively preventing viral eradication. Treatment decreases plasma viral RNA, but viral DNA persists, mostly integrated within the genome of nucleated blood cells. Viral DNA blood levels correlate with comorbidities and the rapidity of viral rebound following treatment interruption. To date, no intervention aiming at decreasing HIV DNA levels below those attained through ART has been successful. This includes use of some integrase inhibitors either as part of ART or in treatment intensification studies...
April 4, 2017: MBio
https://www.readbyqxmd.com/read/28374281/prevention-of-sexually-transmitted-diseases-in-hiv-infected-individuals
#17
REVIEW
Laura Quilter, Shireesha Dhanireddy, Jeanne Marrazzo
Prevention of sexually transmitted infections (STIs) is an important part of the care of the HIV-infected individual. STIs have been associated with increased risk of transmission and acquisition of HIV. Among HIV-infected persons, treatment failures and high recurrence rates of some STIs are more common. Despite the recognized importance of prevention and discussion of sexual health, rates of screening for STIs are suboptimal. Moreover, rates of STIs such as syphilis continue to increase particularly in men who have sex with men (MSM)...
April 3, 2017: Current HIV/AIDS Reports
https://www.readbyqxmd.com/read/28369066/socioeconomic-factors-explain-suboptimal-adherence-to-antiretroviral-therapy-among-hiv-infected-australian-adults-with-viral-suppression
#18
Krista J Siefried, Limin Mao, Stephen Kerr, Lucette A Cysique, Thomas M Gates, John McAllister, Anthony Maynard, John de Wit, Andrew Carr
BACKGROUND: Missing more than one tablet of contemporary antiretroviral therapy (ART) per month increases the risk of virological failure. Recent studies evaluating a comprehensive range of potential risk factors for suboptimal adherence are not available for high-income settings. METHODS: Adults on ART with undetectable viral load (UDVL) were recruited into a national, multi-centre cohort, completing a comprehensive survey assessing demographics, socio-economic indicators, physical health, well-being, life stressors, social supports, HIV disclosure, HIV-related stigma and discrimination, healthcare access, ART regimen, adherence, side effects, costs and treatment beliefs...
2017: PloS One
https://www.readbyqxmd.com/read/28366730/a-randomized-clinical-trial-comparing-cervical-dysplasia-treatment-with-cryotherapy-vs-loop-electrosurgical-excision-procedure-in-hiv-seropositive-women-from-johannesburg-south-africa
#19
Jennifer S Smith, Busola Sanusi, Avril Swarts, Mark Faesen, Simon Levin, Bridgette Goeieman, Sibongile Ramotshela, Ntombiyenkosi Rakhombe, Anna L Williamson, Pam Michelow, Tanvier Omar, Michael G Hudgens, Cynthia Firnhaber
BACKGROUND: Mortality associated with cervical cancer is a public health concern for women, particularly in HIV-seropositive women in resource-limited countries. HIV-seropositive women are at a higher risk of high-grade cervical precancer, which can eventually progress to invasive carcinoma as compared to HIV-seronegative women. It is imperative to identify effective treatment methods for high-grade cervical precursors among HIV-seropositive women. OBJECTIVE: Randomized controlled trial data are needed comparing cryotherapy vs loop electrosurgical excision procedure treatment efficacy in HIV-seropositive women...
March 31, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28361290/efficacy-and-safety-of-atazanavir-ritonavir-based-antiretroviral-therapy-for-hiv-1-infected-subjects-a-systematic-review-and-meta-analysis
#20
REVIEW
Amr Menshawy, Ammar Ismail, Abdelrahman Ibrahim Abushouk, Hussien Ahmed, Esraa Menshawy, Ahmed Elmaraezy, Mohamed Gadelkarim, Mohamed Abdel-Maboud, Attia Attia, Ahmed Negida
Atazanavir (ATZ) is a well-tolerated protease inhibitor that can be boosted with ritonavir (r) to treat infection with resistant strains of human immunodeficiency virus 1 (HIV-1). The aim of this meta-analysis was to compare the efficacy, safety, and metabolic effects of ATZ/r regimen versus commonly used antiretroviral drugs such as lopinavir (LPV) and darunavir (DRV) in HIV-1-infected patients. We searched PubMed, Scopus, Embase and Cochrane CENTRAL, using relevant keywords. Data were extracted from eligible randomized trials and pooled as risk ratios (RR) or standardized mean differences (SMD) in a meta-analysis model using RevMan software...
March 30, 2017: Archives of Virology
keyword
keyword
66741
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"